Search research articles
Contact Us
Filters
Showing results (101-110 of 119) with videos related to
Page
of 12
Sort By:
The Lancet. Oncology
|
March 24, 2020
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, et al.
Lancet (London, England)
|
September 14, 2023
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial
Zev A Wainberg, Davide Melisi, Teresa Macarulla, et al.
Cancer Medicine
|
June 6, 2023
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma
Letizia Procaccio, Valeria Merz, Morena Fasano, et al.
Future Oncology (London, England)
|
October 5, 2017
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough
Lorenzo Fornaro, Valentina Fanotto, Gianna Musettini, et al.
Cancer Research
|
September 8, 2019
Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma
Carla Mottini, Hideo Tomihara, Diego Carrella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2021
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
Timothy A Yap, Maria Vieito, Capucine Baldini, et al.
The Oncologist
|
September 2, 2017
Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy
Valentina Fanotto, Mario Uccello, Irene Pecora, et al.
Nature Communications
|
December 7, 2018
Induction of immunosuppressive functions and NF-κB by FLIP in monocytes
Alessandra Fiore, Stefano Ugel, Francesco De Sanctis, et al.
Cancer Medicine
|
June 26, 2024
Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment
Guido Giordano, Michele Milella, Matteo Landriscina, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 23, 2023
Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial
Davide Melisi, Camilla Zecchetto, Valeria Merz, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 119) with videos related to
Sort By:
Page
of 12
The Lancet. Oncology
|
March 24, 2020
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, et al.
Lancet (London, England)
|
September 14, 2023
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial
Zev A Wainberg, Davide Melisi, Teresa Macarulla, et al.
Cancer Medicine
|
June 6, 2023
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma
Letizia Procaccio, Valeria Merz, Morena Fasano, et al.
Future Oncology (London, England)
|
October 5, 2017
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough
Lorenzo Fornaro, Valentina Fanotto, Gianna Musettini, et al.
Cancer Research
|
September 8, 2019
Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma
Carla Mottini, Hideo Tomihara, Diego Carrella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2021
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
Timothy A Yap, Maria Vieito, Capucine Baldini, et al.
The Oncologist
|
September 2, 2017
Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy
Valentina Fanotto, Mario Uccello, Irene Pecora, et al.
Nature Communications
|
December 7, 2018
Induction of immunosuppressive functions and NF-κB by FLIP in monocytes
Alessandra Fiore, Stefano Ugel, Francesco De Sanctis, et al.
Cancer Medicine
|
June 26, 2024
Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment
Guido Giordano, Michele Milella, Matteo Landriscina, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 23, 2023
Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial
Davide Melisi, Camilla Zecchetto, Valeria Merz, et al.
Page
of 12